Tim Smith

In this interview, Han highlighted new information included in the GOLD 2025 Report regarding utilization of dupilumab and ensifentrine for certain patients with COPD.

In these updates and new sections, the 2025 GOLD report included highlighted climate change, cardiovascular risk, and pulmonary hypertension.

In this cross-sectional survey analysis, new insights were explored regarding clinical practice patterns and treatment outcomes within dermatology practices in the US.

The announcement of the resubmission by Regeneron and Sanofi follows LIBERTY-CUPID phase 3 clinical findings on dupilumab for patients with CSU.

In this analysis in Thailand, video education’s impact on patient guardians’ knowledge was assessed with the aim of reducing eczema severity.

In this analysis, the benefits of 2’-FL for mothers’ offspring with regard to allergies were highlighted by investigators.

A new analysis highlights the seasonal patterns of airborne fungal spores that can be found in the central region of England, with a calendar developed to this same end.

These data on patients with hidradenitis suppurativa point to several factors as being associated with diagnostic wandering.

The acceptance of the investigational gene therapy’s Biologics License Application was announced, with the treatment designed for recessive dystrophic epidermolysis bullosa.

In this latest episode of Lungcast, multiple points of view are highlighted regarding Aspirin-Exacerbated Respiratory Disease (AERD).

This analysis highlighted links between depression, stigmatization, anxiety, and health- and disease-related variables among individuals with HS in Europe.

These results point to the value of awareness among physicians and patients of the risk of psoriasis linked to immunotherapy during cancer care.

These data were explored to identify risk, recommendations, and guidelines related to vaccine-related allergic reactions such as anaphylaxis.

These data on patients in Japan with eczema suggest there was sustained effectiveness in these patients’ clinical signs and in patient-reported outcomes.

In this analysis, patterns of global access to biologic drugs for patients with atopic dermatitis were explored among 50 countries.

In recent findings presented at ACAAI 2024, patients, caregivers, and even emergency medical professionals were shown to face issues with regard to treatment of anaphylaxis reactions.

The Parental Self-efficacy in Managing Anaphylaxis (PSEMA) questionnaire was shown to be effective in assessing self-efficacy of parents in managing their childrens’ conditions.

A sample of some of the most significant developments in pulmonology from October is featured in this Month in Review summary.

The announcement by the FDA resulted from an agency review of data on oral phenylephrine and a determination of its ineffectiveness as an active ingredient.

In this geospatial analysis, findings indicate that geographic regions with more tanning bed facilities tend to report higher melanoma rates.

In this review of the month of October, some of the most notable advancements and news in the field of allergy were highlighted.

This interview with Kraft features a discussion regarding her team’s new data from the BATURA study on albuterol for patients’ asthma exacerbations.

Investigators highlighted the long-term cost-effectiveness of routine HCV screening as well as linkage-to-care for high-risk patients in emergency departments.

Despite the number of individuals with MASLD-related HCC without cirrhosis who report a low FIB-4, current care pathways may not identify such patients for additional assessments.

In this Month in Review summary, some of the most notable advancements and developments in the field of dermatology were highlighted.

The approval by the FDA of minocycline hydrochloride modified release capsules, also known as DFD-29, will allow for treatment of inflammatory lesions and erythema among adults.

In this analysis, investigators identified several markers such as monocyte-high-density lipoprotein cholesterol ratio and C-reactive protein values.

This interview from Fall Clinical highlights the broader implications of the phase 3 data resulting from the ARRECTOR trial on roflumilast foam for those with psoriasis.

This interview following Fall Clinical highlights new phase 3 data on patient-reported outcomes from the ARRECTOR study evaluating roflumilast foam for psoriasis.

This conference review highlights several of the most notable stories and recent data covered by HCPLive at the Fall Clinical Dermatology Conference.